BIIB
$BIIB
Biogen Inc.
Biotech company developing therapies for neurological diseases including Alzheimer's and MS.
Healthcare$249.01
-4.61 (-1.82%)
Day Range$248.02 - $255.53
Prev Close$253.62
Analyst Rating
Strong Buy
25 Buy / 10 Hold / 1 Sell
Price Target
$255.00
2.4% upside
Subscribers
0
Tracking this ticker
Latest Report
Analysis from Oct 31, 2026
BIIB: Q3 Beat, Alzheimer's Data in Focus
Biogen reported a stronger-than-expected Q3 and analysts raised forecasts, while Alzheimer’s data and Apellis integration remain key catalysts. Valuation sits near consensus, limiting near-term upside.
Oct 31, 2026
Previous Reports
Keep exploring
- draft Biogen into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Biogen's peers: Today's sector-level news and moves around the stock